NASDAQ:QTRX - Quanterix Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $22.75 +0.62 (+2.80 %) (As of 02/15/2019 04:00 PM ET)Previous Close$22.75Today's Range$22.34 - $23.0052-Week Range$13.00 - $23.99Volume75,147 shsAverage Volume66,053 shsMarket Capitalization$505.00 millionP/E Ratio-2.74Dividend YieldN/ABeta1.37 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. It develops Simoa HD-1 Analyzer, a sensitive protein detection platform, which analyzes approximately six biomarkers per test; and Quanterix SR-X, which utilizes the same technology and assay kit as the Simoa HD-1 Analyzer. The company's products include kits, such as beads, capture and detector reagents, enzyme reagents, and enzyme substrates to run tests; and consumables, such as proprietary Simoa disks, cuvettes, and disposable tips. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sell its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. Quanterix Corporation has collaboration agreements with DestiNA Genomics to focus on the development of a nucleic acid assay for direct detection and quantification of the liver toxicity biomarker microRNA-122; and OncoGenesis Corp to develop a protein biomarker diagnostic test for cervical health using its Simoa Planar Technology. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Lexington, Massachusetts. Receive QTRX News and Ratings via Email Sign-up to receive the latest news and ratings for QTRX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Analytical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:QTRX Previous Symbol CUSIPN/A Webwww.quanterix.com Phone617-301-9400Debt Debt-to-Equity Ratio0.16 Current Ratio4.11 Quick Ratio3.76Price-To-Earnings Trailing P/E Ratio-2.74 Forward P/E Ratio-18.50 P/E GrowthN/A Sales & Book Value Annual Sales$22.87 million Price / Sales22.08 Cash FlowN/A Price / Cash FlowN/A Book Value$3.02 per share Price / Book7.53Profitability EPS (Most Recent Fiscal Year)($8.30) Net Income$-27,010,000.00 Net Margins-88.72% Return on Equity-52.35% Return on Assets-36.48%Miscellaneous Employees126 Outstanding Shares22,198,000Market Cap$505.00 million OptionableNot Optionable Quanterix (NASDAQ:QTRX) Frequently Asked Questions What is Quanterix's stock symbol? Quanterix trades on the NASDAQ under the ticker symbol "QTRX." When is Quanterix's next earnings date? Quanterix is scheduled to release their next quarterly earnings announcement on Monday, March 18th 2019. View Earnings Estimates for Quanterix. What price target have analysts set for QTRX? 2 analysts have issued 1-year price objectives for Quanterix's stock. Their predictions range from $26.00 to $27.00. On average, they anticipate Quanterix's share price to reach $26.50 in the next year. This suggests a possible upside of 16.5% from the stock's current price. View Analyst Price Targets for Quanterix. What is the consensus analysts' recommendation for Quanterix? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quanterix in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Quanterix. What are Wall Street analysts saying about Quanterix stock? Here are some recent quotes from research analysts about Quanterix stock: 1. According to Zacks Investment Research, "Quanterix Corporation is a developer of tools in high definition diagnostics. The Company focuses on research and diagnostics for brain injuries, heart disease, cancer and other diseases with its technology. It offers Simoa consumables, which include Simoa Discs, Simoa Cuvettes, Simoa Sealing Oil, Simoa Buffers and Disposable Tips. The company services include Simoa Accelerator Lab and custom assay development services. Quanterix Corporation is based in LEXINGTON, United States. " (1/25/2019) 2. Canaccord Genuity analysts commented, "We think investors should own QTRX as it targets growth across 4 phases: 1) expansion in the life sciences research, followed by possible entry into new markets in 2) companion diagnostics; 3) point-of-care diagnostics; and 4) precision health and wellness screening, a $38 billion TAM. We reiterate our BUY rating and $27 PT. Q3 beat. Q3 revenues of $10.6M (+85% Y/Y, +61% adj.) topped our $8.4M (+47%)/ Street’s $8.3M, and included a 1-time payment of $1.3M from its licensing termination with BioMérieux. Product revs of $6.0M (+82% Y/Y) beat our $5.0M, while service revs (ex the 1-timer) of $3.0M was light of our $3.4M. QTRX beat us on consumables (+100% Y/Y beat our +70%) and instruments (+58% Y/Y beat our +30%). ~46% were in line with our 46.5%E. OPEX of $13.3M was above our $10.5ME. Net loss of ($7.7M) exceeded our ($6.9ME)." (11/7/2018) Has Quanterix been receiving favorable news coverage? Press coverage about QTRX stock has been trending neutral recently, InfoTrie reports. The research group rates the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Quanterix earned a news impact score of 0.2 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near future. Who are some of Quanterix's key competitors? Some companies that are related to Quanterix include Accelerate Diagnostics (AXDX), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Eyepoint Pharmaceuticals (EYPT), Harvard Bioscience (HBIO), HTG Molecular Diagnostics (HTGM), Arrayit (ARYC), BioNano Genomics (BNGO), Aethlon Medical (AEMD), Scientific Industries (SCND), Precipio (PRPO), Pressure Biosciences (PBIO) and PositiveID (PSID). Who are Quanterix's key executives? Quanterix's management team includes the folowing people: Mr. E. Kevin Hrusovsky, Chairman, Pres & CEO (Age 58)Dr. David R. Walt, Co-Founder, Chairman of Scientific Advisory Board & Director (Age 66)Mr. Joseph S. Driscoll, Chief Financial Officer (Age 54)Dr. David C. Duffy Ph.D., Sr. VP of R&D and CTO (Age 48)Mr. Paul M. Meister M.B.A., Director (Age 66) When did Quanterix IPO? (QTRX) raised $50 million in an initial public offering (IPO) on Thursday, December 7th 2017. The company issued 3,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morga and Leerink Partners served as the underwriters for the IPO and BTIG and Evercore ISI were co-managers. Who are Quanterix's major shareholders? Quanterix's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Royce & Associates LP (3.27%), BlackRock Inc. (2.97%), Jennison Associates LLC (1.34%), Bellevue Group AG (1.29%), Diag Capital Management LP (1.01%) and Northern Trust Corp (0.44%). Company insiders that own Quanterix stock include David R Walt, E Kevin Hrusovsky, Ernest Orticerio, John M Connolly, Joseph Driscoll and Venture Fund Viii Overage Arch. View Institutional Ownership Trends for Quanterix. Which major investors are selling Quanterix stock? QTRX stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Bellevue Group AG, Royce & Associates LP, Barclays PLC, Acadian Asset Management LLC, Northern Trust Corp and Citigroup Inc.. Company insiders that have sold Quanterix company stock in the last year include E Kevin Hrusovsky, Ernest Orticerio and Joseph Driscoll. View Insider Buying and Selling for Quanterix. Which major investors are buying Quanterix stock? QTRX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Diag Capital Management LP, Squarepoint Ops LLC, Geode Capital Management LLC, Brandywine Managers LLC, Rhumbline Advisers, Granite Investment Partners LLC and Macquarie Group Ltd.. Company insiders that have bought Quanterix stock in the last two years include David R Walt, E Kevin Hrusovsky, John M Connolly and Venture Fund Viii Overage Arch. View Insider Buying and Selling for Quanterix. How do I buy shares of Quanterix? Shares of QTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Quanterix's stock price today? One share of QTRX stock can currently be purchased for approximately $22.75. How big of a company is Quanterix? Quanterix has a market capitalization of $505.00 million and generates $22.87 million in revenue each year. The company earns $-27,010,000.00 in net income (profit) each year or ($8.30) on an earnings per share basis. Quanterix employs 126 workers across the globe. What is Quanterix's official website? The official website for Quanterix is http://www.quanterix.com. How can I contact Quanterix? Quanterix's mailing address is 113 HARTWELL AVENUE, LEXINGTON MA, 02421. The company can be reached via phone at 617-301-9400. MarketBeat Community Rating for Quanterix (NASDAQ QTRX)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 144 (Vote Outperform)Underperform Votes: 165 (Vote Underperform)Total Votes: 309MarketBeat's community ratings are surveys of what our community members think about Quanterix and other stocks. Vote "Outperform" if you believe QTRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QTRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/16/2019 by MarketBeat.com StaffFeatured Article: What is cost of equity?